Frazier Life Sciences
VC Fund
Boston, United States
Frazier Life Sciences is a healthcare investment firm that focuses on companies developing novel therapeutics, guiding them from formation to scaling. It engages in early stage venture, late stage venture, private equity, and seed investments, demonstrating a broad commitment to healthcare innovation.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 58%
- Fund size:
- $1.7B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Frazier Life Sciences invests in
Stages Frazier Life Sciences invests in
Countries Frazier Life Sciences invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 19 (100%)
- Health Care 11 (58%)
- Therapeutics 8 (42%)
- Medical 6 (32%)
- Life Science 4 (21%)
Stage
- Series A 9 (47%)
- Post-IPO Equity 5 (26%)
- Series B 3 (16%)
- Series C 1 (5%)
- Series D 1 (5%)
Country
- United States 12 (63%)
- United Kingdom 2 (11%)
- France 1 (5%)
- Germany 1 (5%)
- Switzerland 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anna H. Chen
Principal
|
Principal | Total investments: 2 | Find email | |
Jamie Brush
General Partner and Portfolio Manager
|
General Partner and Portfolio Manager | Total investments: 1 | Find email | |
Kevin Li
Partner
|
Partner | Total investments: 3 | Find email | |
Lauren Mifflin
Vice President of Company Creation
|
Vice President of Company Creation | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA(R), is in the late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Itmaintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. | $50M / Post-IPO Equity / Jul 23, 2026 | ||
| RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passiveimmunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations.RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease. | $112.5M / Series A / Jun 24, 2026 | ||
| cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions. | $180M / Series A / May 20, 2026 | ||
| Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M / Post-IPO Equity / Apr 30, 2026 | ||
| Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M / Post-IPO Equity / Apr 16, 2026 | ||
| Sidewinder Therapeutics develops bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors. Their mission is to create life-saving therapies through precision therapeutics. | $137M / Series B / Apr 08, 2026 | ||
| Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils. | $87.1M / Series A / Mar 24, 2026 | ||
| Vima Therapeutics operates as a biotechnology company.Vima Therapeutics creates a new era in treatments for dystonia and related movement disorders. | $40M / Series A / Mar 11, 2026 | ||
| AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions. | $200M / Series A / Jan 09, 2026 | ||
| iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics usingtransient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. | $26M / Post-IPO Equity / Jan 09, 2026 | ||
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Frazier Life Sciences invest in?
Frazier Life Sciences invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Post-IPO Equity stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Frazier Life Sciences?
Public channels for Frazier Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Frazier Life Sciences?
The team at Frazier Life Sciences includes Anna H. Chen (Principal), Jamie Brush (General Partner and Portfolio Manager) and Kevin Li (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
